© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Skin Cancers
Early Trials in Melanoma Show Better Response After 1 Year
May 12, 2020
Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.
Cemiplimab Induces Significant Responses in Second-line Basal Cell Carcinoma
May 05, 2020
"...These important new results further demonstrate Libtayo’s potential in patients with difficult-to-treat, non-melanoma skin cancers."
Engineered Cellular Therapies Enter Treatment Landscape of Melanoma
May 04, 2020
In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.
Combination Regimens Inspire Hope for the Treatment of Melanoma
May 04, 2020
In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.
Positive Treatment Response Reinforced With SGX301 in Cutaneous T-Cell Lymphoma
April 30, 2020
"As anticipated, the data continues to become more compelling with extended SGX301 treatment."
ILLUMINATE-204 Update: Promising Results Reported With Tilsotolimod Plus Ipilimumab in Advanced Melanoma
April 21, 2020
"The clinical benefit suggested for these anti-PD-1 refractory melanoma patients with limited treatment options includes stabilization of disease and even responses, which is creating hope that this combination might be of benefit to patients in the PD-1 refractory setting."
Evaluating Prognosis of Patients With Ocular Melanoma
April 17, 2020
Ragini Kudchadkar, MD, discusses the overall prognosis of patients with ocular melanoma.
Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced Melanoma
April 15, 2020
Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the design and efficacy of the phase III CheckMate 067 trial for patients with advanced melanoma.
Anti-Cancer Agents as Frontline Treatment of MPNs Lead to Higher Probability of Non-Melanoma Skin Cancers
April 10, 2020
Exposure to ruxolitinib, hydroxyurea, and pipobroman as first-line treatment of Philadelphia-negative myeloproliferative neoplasms alone or in combination with other cytoreductive treatment may increase the probability of patients developing non-melanoma skin cancer, highlighting a need for active dermatological surveillance of these patients, according to findings from the MPN-K study, published in Leukemia.
Novel Intralesional Injection Achieves Complete Histological Clearance in Squamous Cell Carcinoma
April 10, 2020
Treatment with STP705 led to the achievement of complete histological clearance of squamous cell carcinoma in situ in a large proportion of patients, meeting the primary end point of the study, according to an interim analysis of the first 3 cohorts in an ongoing phase II clinical trial in patients with non-melanoma skin cancer announced by Sirnaomics Inc.